Scarica l'app Stockscreener
210.23
1.95%
-4.19
Dopo l'orario di chiusura:
210.50
0.27
+0.13%
Precedente Chiudi:
$214.42
Aprire:
$214.25
Volume 24 ore:
636.18K
Relative Volume:
0.72
Capitalizzazione di mercato:
$13.65B
Reddito:
$4.44B
Utile/perdita netta:
$29.49M
Rapporto P/E:
-11,425.54
EPS:
-0.0184
Flusso di cassa netto:
$1.19B
1 W Prestazione:
-3.75%
1M Prestazione:
-13.70%
6M Prestazione:
+6.27%
1 anno Prestazione:
+56.60%
Intervallo 1D:
$208.15
$214.78
Intervallo di 1 settimana:
$208.15
$221.99
Portata 52W:
$128.80
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
210.23 | 13.65B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-30 | Iniziato | Citigroup | Buy |
| 2026-09-24 | Ripresa | Goldman | Buy |
| 2026-07-17 | Iniziato | Canaccord Genuity | Buy |
| 2026-06-09 | Ripresa | Truist | Buy |
| 2026-05-22 | Iniziato | Bernstein | Mkt Perform |
| 2026-05-19 | Aggiornamento | UBS | Neutral → Buy |
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
Jim Cramer Gives Green Light To This Health Care Stock - Benzinga
Jazz Pharmaceuticals (JAZZ) President & CEO Renee Gala Sells 2,0 - GuruFocus
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Zacks Investment Research
Jazz Pharmaceuticals plc (J7Z.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
The top 12 companies hiring in biopharma now - BioSpace
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks - Yahoo Finance
What Comes Next for Jazz Pharmaceuticals (NASDAQ:JAZZ)? - Kalkine Media
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - Yahoo Finance
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com UK
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - tradingview.com
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead - Yahoo Finance
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com UK
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com Canada
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com UK
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com South Africa
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Canada
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - investing.com
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jazz Pharmaceuticals Plc Azioni (JAZZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GALA RENEE D | President & CEO |
Oct 06 '26 |
Sale |
236.40 |
2,000 |
472,800 |
141,394 |
| RENEE D GALA | Officer |
Oct 06 '26 |
Proposed Sale |
236.40 |
2,000 |
472,800 |
0 |
| COZADD BRUCE C | Director |
Oct 01 '26 |
Sale |
230.33 |
6,000 |
1,381,980 |
345,875 |
| Bruce C Cozadd | Officer |
Oct 01 '26 |
Proposed Sale |
230.33 |
6,000 |
1,381,980 |
0 |
| Patil Neena M | EVP & Chief Legal Officer |
Sep 10 '26 |
Sale |
240.94 |
1,200 |
289,128 |
47,671 |
| NEENA PATIL | Officer |
Sep 10 '26 |
Proposed Sale |
240.94 |
1,200 |
289,128 |
0 |
| GALA RENEE D | President & CEO |
Sep 08 '26 |
Sale |
243.03 |
2,000 |
486,060 |
143,394 |
| RENEE D GALA | Officer |
Sep 08 '26 |
Proposed Sale |
243.03 |
2,000 |
486,060 |
0 |
| Henderson Mary Elizabeth | Director |
Sep 08 '26 |
Proposed Sale |
246.81 |
2,691 |
664,166 |
0 |
| COZADD BRUCE C | Director |
Sep 01 '26 |
Sale |
250.13 |
6,000 |
1,500,780 |
351,875 |
0.27%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):